Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immunome (IMNM)
NASDAQ:IMNM
Immunome (IMNM) Stock Price & Analysis
183 Followers
IMNM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.13 - $30.96
Previous Close$13.99
Volume499.00K
Average Volume (3M)1.01M
Market Cap
$838.96M
Enterprise Value$530.47M
Total Cash (Recent Filing)$309.70M
Total Debt (Recent Filing)$1.21M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Aug 15, 2024EPS Estimate
-$0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.54
Shares Outstanding59,968,868
10 Day Avg. Volume1,119,909
30 Day Avg. Volume1,011,143
Standard Deviation0.44
R-Squared0.05
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)6.22
Price to Sales (P/S)724.99
Price to Cash Flow (P/CF)-10.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue41.83
Enterprise Value/Gross Profit37.84
Enterprise Value/Ebitda-13.50
Forecast
1Y Price Target
$30.50Price Target Upside122.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Immunome News
PremiumCompany Announcements
Immunome Announces Executive Shift, Welcomes New Accounting OfficerBulls Say, Bears Say
Bulls Say
Clinical TrialsThe delay in the RINGSIDE trial could suggest the drug is performing better than expected.
Management And StrategyValuable know-how in drug development. Management has a strong track record at Seagen, leading Adcetris and Padcev to market and bringing in differentiated assets.
Pipeline And DevelopmentThe pipeline now combines a pivotal stage asset and multiple early-stage programs in areas that are of significant investor interest.
Bears Say
Drug DevelopmentThe ability to replicate Phase 2 efficacy in the larger Phase 3 is critical for valuation tied to the success of AL102.
Financial CommitmentsIMNM is responsible for up to $142 million in clinical development and regulatory milestones, as well as up to $50 million for commercial milestones, which signifies financial commitments that could impact cash flow.
Share DilutionThe price target for IMNM has been lowered to $38 from $40, primarily due to the share dilution.
---
Ownership Overview
5.52% Insiders
15.89% Mutual Funds
9.61% Other Institutional Investors
68.98% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IMNM FAQ
What was Immunome’s price range in the past 12 months?
Immunome lowest stock price was $6.13 and its highest was $30.96 in the past 12 months.
What is Immunome’s market cap?
Currently, no data Available
When is Immunome’s upcoming earnings report date?
Immunome’s upcoming earnings report date is Aug 15, 2024 which is in 28 days.
How were Immunome’s earnings last quarter?
Immunome released its earnings results on May 14, 2024. The company reported -$2.51 earnings per share for the quarter, missing the consensus estimate of -$0.68 by -$1.83.
Is Immunome overvalued?
According to Wall Street analysts Immunome’s price is currently Undervalued.
Does Immunome pay dividends?
Immunome does not currently pay dividends.
What is Immunome’s EPS estimate?
Immunome’s EPS estimate is -$0.37.
How many shares outstanding does Immunome have?
Immunome has 59,968,870 shares outstanding.
What happened to Immunome’s price movement after its last earnings report?
Immunome reported an EPS of -$2.51 in its last earnings report, missing expectations of -$0.68. Following the earnings report the stock price went down -5.701%.
Which hedge fund is a major shareholder of Immunome?
Among the largest hedge funds holding Immunome’s share is Woodline Partners LP. It holds Immunome’s shares valued at 33M.
---
Immunome Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.50 (122.47% Upside)
$30.50 (122.47% Upside)
Blogger Sentiment
Bullish
IMNM Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
80.05%
12-Months-Change
Fundamentals
Return on Equity
-154.98%
Trailing 12-Months
Asset Growth
564.58%
Trailing 12-Months
Company Description
Immunome
Immunome Inc is a biopharmaceutical company engaged in the discovery and development of novel antibody-based drugs. The company's proprietary discovery platform identifies novel therapeutic antibodies and their targets by leveraging highly educated components of the immune system, memory B cells, from patients who have learned to fight off their disease. It is developing treatments for treating cancer and other infectious diseases.
---
IMNM Stock 12 Month Forecast
Average Price Target
$30.50
▲(122.47% Upside)
Technical Analysis
Best Analysts Covering IMNM
1 Year
1 Year Success Rate
1/3 ratings generated profit
1 Year Average Return
-9.17%
assigned a buy rating 2 months ago
Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -9.17% per trade.
---